Skip to main content
AstraZeneca PLC logo

AstraZeneca PLC — Investor Relations & Filings

Ticker · AZN ISIN · GB0009895292 LEI · PY6ZZQWO2IZFZC3IOL08 IL Manufacturing
Open in API
Filings indexed 3,304 across all filing types
Latest filing 2023-06-09 Foreign Filer Report
Country GB United Kingdom
Listing IL AZN

About AstraZeneca PLC

https://www.astrazeneca.com/

AstraZeneca PLC is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialization of prescription medicines. The company's portfolio is concentrated on several main therapy areas, including Oncology; Cardiovascular, Renal & Metabolism; and Respiratory & Immunology. AstraZeneca is committed to advancing healthcare through a robust research and development pipeline, aiming to deliver innovative medicines that address significant unmet medical needs for millions of patients worldwide. The company leverages scientific innovation to transform the future of healthcare and improve patient outcomes.

Recent filings

Filing Released Lang Actions
ASTRAZENECA AGREEMENT WITH QUELL THERAPEUTICS
Foreign Filer Report
2023-06-09 English
nirsevimab recommended for infant RSV protection
Regulatory Filings Classification · 1% confidence The document is a press release dated June 9, 2023, announcing that the FDA Advisory Committee (AMDAC) unanimously recommended AstraZeneca and Sanofi's nirsevimab for preventing RSV LRTD in infants. It details the positive vote, the favorable benefit-risk profile, and the expected PDUFA date in Q3 2023. This type of announcement, which communicates a significant regulatory milestone (an advisory committee recommendation) and provides context about a drug/product, fits best under the category of a general regulatory announcement or press release that doesn't fit a more specific financial report type. Since it is a formal announcement regarding regulatory progress and clinical data, and it is not a full financial report (10-K, IR), earnings release (ER), or a transcript (CT), the most appropriate classification is Regulatory Filings (RNS), which serves as a broad category for official company announcements not covered elsewhere. The document length is substantial (over 26k characters), suggesting it is the full announcement, not just a brief notice of publication (which would be RPA).
2023-06-09 English
AstraZeneca agreement with Quell Therapeutics
M&A Activity Classification · 1% confidence The document begins with an 'RNS Number' and is dated '09 June 2023'. It announces a specific corporate event: 'AstraZeneca announces agreement with Quell Therapeutics to develop, manufacture and commercialise engineered T-regulatory cell therapies for autoimmune diseases'. This structure—a brief announcement of a significant corporate action (collaboration/licensing deal) disseminated via the Regulatory News Service (RNS)—is characteristic of a general regulatory announcement that doesn't fit the highly specific categories like 10-K, ER, or DIV. Since it is a formal regulatory news service release and doesn't fit other specific categories like M&A (TAR) or Capital Change (CAP), the most appropriate classification is the general regulatory filing category, RNS.
2023-06-09 English
IMFINZI IMPROVED PCR IN GASTRIC AND GEJ CANCERS
Foreign Filer Report
2023-06-02 English
Imfinzi improved pCR in gastric and GEJ cancers
Regulatory Filings Classification · 1% confidence The document begins with an 'RNS Number' and a date, indicating it is a regulatory announcement disseminated via the London Stock Exchange's RNS service. The content is a press release detailing positive high-level results from a Phase III clinical trial (MATTERHORN) for a drug (Imfinzi). This type of announcement, which communicates significant corporate or clinical development news to the market via an official channel like RNS, fits best under the general 'Regulatory Filings' category, as it is not a full financial report (10-K, IR), an earnings release (ER), or a specific management/board change (MANG). Since it is a general regulatory news service release that doesn't fit the other specific categories, RNS is the appropriate classification.
2023-06-02 English
BLOCK LISTING INTERIM REVIEW
Foreign Filer Report
2023-06-01 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.